Terms: = Prostate cancer AND KMT2D, ENSG00000167548, 8085, MLL2 AND Treatment
11 results:
1. Epigenetic-focused CRISPR/Cas9 screen identifies (absent, small, or homeotic)2-like protein (ASH2L) as a regulator of glioblastoma cell survival.
Ozyerli-Goknar E; Kala EY; Aksu AC; Bulut I; Cingöz A; Nizamuddin S; Biniossek M; Seker-Polat F; Morova T; Aztekin C; Kung SHY; Syed H; Tuncbag N; Gönen M; Philpott M; Cribbs AP; Acilan C; Lack NA; Onder TT; Timmers HTM; Bagci-Onder T
Cell Commun Signal; 2023 Nov; 21(1):328. PubMed ID: 37974198
[TBL] [Abstract] [Full Text] [Related]
2. In-silico identification of frequently mutated genes and their co-enriched metabolic pathways associated with prostate cancer progression.
Singh AN; Sharma N
Andrologia; 2021 Dec; 53(11):e14236. PubMed ID: 34468989
[TBL] [Abstract] [Full Text] [Related]
3. Economic Outcomes in Patients with Chemotherapy-Naïve Metastatic Castration-Resistant prostate cancer Treated with Enzalutamide or Abiraterone Acetate Plus Prednisone.
Ramaswamy K; Lechpammer S; Mardekian J; Huang A; Schultz NM; Sandin R; Wang L; Baser O; George DJ
Adv Ther; 2020 May; 37(5):2083-2097. PubMed ID: 32112280
[TBL] [Abstract] [Full Text] [Related]
4. Integrative Exome Sequencing Analysis in Castration-Resistant prostate cancer in Chinese Population.
Hao L; Li H; Zhang S; Yang Y; Xu Z; Zhang Y; Liu Z
Curr Pharm Biotechnol; 2020; 21(2):140-148. PubMed ID: 31580249
[TBL] [Abstract] [Full Text] [Related]
5. Loss of kmt2d induces prostate cancer ROS-mediated DNA damage by suppressing the enhancer activity and DNA binding of antioxidant transcription factor FOXO3.
Lv S; Wen H; Shan X; Li J; Wu Y; Yu X; Huang W; Wei Q
Epigenetics; 2019 Dec; 14(12):1194-1208. PubMed ID: 31232159
[TBL] [Abstract] [Full Text] [Related]
6. Folate-targeted pH-responsive calcium zoledronate nanoscale metal-organic frameworks: Turning a bone antiresorptive agent into an anticancer therapeutic.
Au KM; Satterlee A; Min Y; Tian X; Kim YS; Caster JM; Zhang L; Zhang T; Huang L; Wang AZ
Biomaterials; 2016 Mar; 82():178-93. PubMed ID: 26763733
[TBL] [Abstract] [Full Text] [Related]
7. The mutational landscape of lethal castration-resistant prostate cancer.
Grasso CS; Wu YM; Robinson DR; Cao X; Dhanasekaran SM; Khan AP; Quist MJ; Jing X; Lonigro RJ; Brenner JC; Asangani IA; Ateeq B; Chun SY; Siddiqui J; Sam L; Anstett M; Mehra R; Prensner JR; Palanisamy N; Ryslik GA; Vandin F; Raphael BJ; Kunju LP; Rhodes DR; Pienta KJ; Chinnaiyan AM; Tomlins SA
Nature; 2012 Jul; 487(7406):239-43. PubMed ID: 22722839
[TBL] [Abstract] [Full Text] [Related]
8. cancer of the prostate.
Bracarda S; de Cobelli O; Greco C; Prayer-Galetti T; Valdagni R; Gatta G; de Braud F; Bartsch G
Crit Rev Oncol Hematol; 2005 Dec; 56(3):379-96. PubMed ID: 16310371
[TBL] [Abstract] [Full Text] [Related]
9. Feasibility study combining low dose rate (192)Ir brachytherapy and external beam radiotherapy aiming at delivering 80-85 Gy to prostatic adenocarcinoma.
Nickers P; Coppers L; Beauduin M; Darimont M; de Leval J; Deneufbourg J
Radiother Oncol; 2000 Apr; 55(1):41-7. PubMed ID: 10788687
[TBL] [Abstract] [Full Text] [Related]
10. Acute morbidity of radiation therapy for prostate carcinoma.
Franklin CI
Australas Radiol; 1996 May; 40(2):140-5. PubMed ID: 8687346
[TBL] [Abstract] [Full Text] [Related]
11. Hormone therapy of prostatic bone metastases.
Huben RP
Adv Exp Med Biol; 1992; 324():305-16. PubMed ID: 1492625
[TBL] [Abstract] [Full Text] [Related]
